These two classes of medications serve completely different purposes. Anticoagulants are used to prevent new and future cases of blood clots that can lead to PE. They may also reduce the size of a ...

Physicians should also carefully explain to the patients the potential benefits and some adverse reactions, such as dyspepsia with dabigatran, associated with these new oral agents and the ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and ...

DOACs only and warfarin only are more likely to be prescribed to Medicare beneficiaries seeing clinicians in rural areas compared with urban areas.

The oral and reversible drug has been uniquely designed to overcome many of ... that inversely correlate with major events. Tecarfarin is the only new anticoagulant being developed for patients with ...

In early September, Cadrenal leadership met with the U.S. Food and Drug Administration ... a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for ...

Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, is the leading cause of acquired heart disease in developed countries, with the potential of ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The oral and reversible drug has been uniquely ... developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with ...

The continued quest for an 'ideal anticoagulant' led to the US FDA's recent approval of dabigatran etexilate, a prodrug for dabigatran (Pradaxa®, Boehringer Ingelheim), rivaroxaban, a Factor Xa ...